149 related articles for article (PubMed ID: 34944888)
1. Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma.
Sato Y; Nakano K; Wang X; Fukuda N; Urasaki T; Ohmoto A; Hayashi N; Yunokawa M; Ono M; Tomomatsu J; Saito M; Minami Y; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944888
[TBL] [Abstract][Full Text] [Related]
2. Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Kawaguchi K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Hayashi N; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Cancer Diagn Progn; 2021; 1(4):303-308. PubMed ID: 35403143
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
4. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
Shimada E; Endo M; Matsumoto Y; Tsuchihashi K; Ito M; Kusaba H; Nabeshima A; Nawata T; Maekawa A; Matsunobu T; Setsu N; Fujiwara T; Iida K; Nakagawa M; Hirose T; Kanahori M; Oyama R; Isobe T; Ariyama H; Kohashi K; Yamamoto H; Oda Y; Iwamoto Y; Akashi K; Baba E; Nakashima Y
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768491
[TBL] [Abstract][Full Text] [Related]
5. Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study.
Mirili C; Paydaş S; Guney IB; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M; Seydaoglu G
Cancer Manag Res; 2019; 11():3445-3453. PubMed ID: 31114378
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin.
Ishihara S; Ogura K; Maejima A; Shimoi T; Sudo K; Kojima Y; Fukushima S; Osaki S; Kobayashi E; Iwata S; Matsui Y; Yonemori K; Kawai A
Jpn J Clin Oncol; 2023 Jun; 53(6):494-500. PubMed ID: 36989466
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Kobayashi H; Okuma T; Oka H; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Sato K; Abe S; Kawano H; Goto T; Tanaka S
Int J Clin Oncol; 2018 Apr; 23(2):368-374. PubMed ID: 29086877
[TBL] [Abstract][Full Text] [Related]
8. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
9. Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.
Imai T; Kojima Y; Shimoi T; Aiba H; Okuma HS; Saito A; Kita S; Yamamoto K; Maejima A; Nishikawa T; Sudo K; Noguchi E; Yoshida A; Matsui Y; Iwata S; Kobayashi E; Kawai A; Udagawa R; Fujiwara Y; Yonemori K
Anticancer Res; 2024 May; 44(5):2125-2132. PubMed ID: 38677749
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Importance of Inflammatory Indexes in Patients Treated by Pazopanib for Soft Tissue Sarcoma.
Koseci T; Haksoyler V; Olgun P; Ata S; Nayir E; Duman BB; Cil T
Clin Lab; 2022 Feb; 68(2):. PubMed ID: 35142203
[TBL] [Abstract][Full Text] [Related]
11. Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and survival in undifferentiated pleomorphic sarcoma (NLR, PLR, and overall survival in UPS).
Tepper SC; Lee L; Fice MP; Jones CM; Klein ED; Vijayakumar G; Batus M; Colman MW; Gitelis S; Blank AT
Surg Oncol; 2023 Aug; 49():101949. PubMed ID: 37263041
[TBL] [Abstract][Full Text] [Related]
12. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
Mochizuki T; Ikegami M; Akiyama T
Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
[TBL] [Abstract][Full Text] [Related]
13. Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin.
Fausti V; De Vita A; Vanni S; Ghini V; Gurrieri L; Riva N; Casadei R; Maraldi M; Ercolani G; Cavaliere D; Pacilio CA; Pieri F; Foca F; Bongiovanni A; Ranallo N; Calpona S; Frassineti GL; Ibrahim T; Mercatali L
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831421
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
15. The baseline neutrophil lymphocyte ratio predicts survival in soft-tissue sarcoma: A 17-year cohort study.
Griffiths TT; Arango MWF; Smith IM; Wade RG
J Plast Reconstr Aesthet Surg; 2022 Apr; 75(4):1372-1379. PubMed ID: 34955395
[TBL] [Abstract][Full Text] [Related]
16. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
Erdogan B; Kostek O; Bekir Hacioglu M; Gokyer A; Kucukarda A; Ozcan E; Gokmen I; Uzunoglu S; Cicin I
J BUON; 2021; 26(5):2196-2201. PubMed ID: 34761635
[TBL] [Abstract][Full Text] [Related]
17. Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma.
Que Y; Qiu H; Li Y; Chen Y; Xiao W; Zhou Z; Zhang X
BMC Cancer; 2015 Oct; 15():648. PubMed ID: 26432433
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib.
Hidalgo-Ríos S; Carrillo-García J; Moura DS; Stacchiotti S; López-Pousa A; Redondo A; Italiano A; Gutiérrez A; Grignani G; Hindi N; López-Guerrero JA; Muro XGD; Trufero JM; Palmerini E; García AS; Bernabeu D; Le Cesne A; Casali PG; Blay JY; Cruz Jurado J; Martin-Broto J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077723
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
[No Abstract] [Full Text] [Related]
20. Survival analysis of patients with recurrent or metastatic soft tissue sarcoma who were treated by cryoablation: A real-world retrospective study.
Wu Q; Li J; Yang W
J Cancer Res Ther; 2021 Dec; 17(7):1736-1741. PubMed ID: 35381747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
